Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.
Ocugen has raised $115.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in May 2026.
Ocugen's investors include Janus Henderson Investors, Avenue Capital Group, RTW Investments, ROTH Capital Partners, Abdi Ibrahim Pharmaceuticals.
Ocugen is headquartered in Malvern, United States.
Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.
Ocugen is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ocugen — Funding & Investors." VCBacked, May 4, 2026, https://www.vcbacked.co/company/ocugen. Accessed July 19, 2026.
VCBacked. (2026). Ocugen — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/ocugen
{{cite web |title=Ocugen — Funding & Investors |url=https://www.vcbacked.co/company/ocugen |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated